Literature DB >> 20871399

The role of mucosal immunity and host genetics in defining intestinal commensal bacteria.

Jonathan Hansen1, Ajay Gulati, R Balfour Sartor.   

Abstract

PURPOSE OF REVIEW: Dramatic advances in molecular characterization of the largely noncultivable enteric microbiota have facilitated better understanding of the composition of this complex ecosystem at broad phylogenetic levels. This review outlines current understanding of mechanisms by which commensal bacteria are controlled and shaped into functional communities by innate and adaptive immune responses, antimicrobial peptides produced by epithelial cells and host genetic factors. RECENT
FINDINGS: Secretory IgA, which targets enteric bacteria, regulates the number, composition, and function of luminal bacteria. Likewise, epithelial production of antimicrobial peptides helps control enteric microbiota growth, translocation, and perhaps composition. The developing role of innate signaling pathways, such as Toll-like receptors and NOD2, is beginning to be studied, with dysbiosis following their genetic deletion. Inflammation and effector immune responses lead to decreased diversity and selective alterations of functionally active bacterial species such as Escherichia coli and Faecalibacterium prausnitzii that have proinflammatory and protective activities, respectively. Studies of humans, mice, and comparative species indicate that both genetic and early environmental factors influence the development of a stable intestinal microbiota.
SUMMARY: Genetic and mucosal immunity strongly influence the composition and function of enteric commensal bacteria. This understanding should help develop strategies to correct dysfunctional altered microbiota in genetically susceptible individuals, better diagnose and correct potential dysbiosis in high-risk individuals at a preclinical stage, and therapeutically target pathogenic bacterial species that help drive chronic inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20871399      PMCID: PMC3733357          DOI: 10.1097/MOG.0b013e32833f1195

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  63 in total

1.  Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis.

Authors:  Jun Nishikawa; Takahiko Kudo; Shinji Sakata; Yoshimi Benno; Toshiro Sugiyama
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

2.  Low counts of Faecalibacterium prausnitzii in colitis microbiota.

Authors:  H Sokol; P Seksik; J P Furet; O Firmesse; I Nion-Larmurier; L Beaugerie; J Cosnes; G Corthier; P Marteau; J Doré
Journal:  Inflamm Bowel Dis       Date:  2009-08       Impact factor: 5.325

3.  Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease.

Authors:  Margarita Martinez-Medina; Xavier Aldeguer; Mireia Lopez-Siles; Ferran González-Huix; Carles López-Oliu; Ghizlane Dahbi; Jesus E Blanco; Jorge Blanco; L Jesus Garcia-Gil; Arlette Darfeuille-Michaud
Journal:  Inflamm Bowel Dis       Date:  2009-06       Impact factor: 5.325

4.  Bacteria and bacterial rRNA genes associated with the development of colitis in IL-10(-/-) mice.

Authors:  Jingxiao Ye; Jimmy W Lee; Laura L Presley; Elizabeth Bent; Bo Wei; Jonathan Braun; Neal L Schiller; Daniel S Straus; James Borneman
Journal:  Inflamm Bowel Dis       Date:  2008-08       Impact factor: 5.325

5.  Phylogenetic background, virulence gene profiles, and genomic diversity in commensal Escherichia coli isolated from ten mammal species living in one zoo.

Authors:  Katarzyna Baldy-Chudzik; Paweł Mackiewicz; Michał Stosik
Journal:  Vet Microbiol       Date:  2008-03-04       Impact factor: 3.293

6.  Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.

Authors:  Harry Sokol; Bénédicte Pigneur; Laurie Watterlot; Omar Lakhdari; Luis G Bermúdez-Humarán; Jean-Jacques Gratadoux; Sébastien Blugeon; Chantal Bridonneau; Jean-Pierre Furet; Gérard Corthier; Corinne Grangette; Nadia Vasquez; Philippe Pochart; Germain Trugnan; Ginette Thomas; Hervé M Blottière; Joël Doré; Philippe Marteau; Philippe Seksik; Philippe Langella
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

7.  Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease.

Authors:  Ben Willing; Jonas Halfvarson; Johan Dicksved; Magnus Rosenquist; Gunnar Järnerot; Lars Engstrand; Curt Tysk; Janet K Jansson
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

8.  Multidrug resistance gene deficient (mdr1a-/-) mice have an altered caecal microbiota that precedes the onset of intestinal inflammation.

Authors:  K Nones; B Knoch; Y E M Dommels; G Paturi; C Butts; W C McNabb; N C Roy
Journal:  J Appl Microbiol       Date:  2009-03-03       Impact factor: 3.772

9.  A core gut microbiome in obese and lean twins.

Authors:  Peter J Turnbaugh; Micah Hamady; Tanya Yatsunenko; Brandi L Cantarel; Alexis Duncan; Ruth E Ley; Mitchell L Sogin; William J Jones; Bruce A Roe; Jason P Affourtit; Michael Egholm; Bernard Henrissat; Andrew C Heath; Rob Knight; Jeffrey I Gordon
Journal:  Nature       Date:  2008-11-30       Impact factor: 49.962

Review 10.  Worlds within worlds: evolution of the vertebrate gut microbiota.

Authors:  Ruth E Ley; Catherine A Lozupone; Micah Hamady; Rob Knight; Jeffrey I Gordon
Journal:  Nat Rev Microbiol       Date:  2008-10       Impact factor: 60.633

View more
  55 in total

Review 1.  The potter's wheel: the host's role in sculpting its microbiota.

Authors:  Charles L Bevins; Nita H Salzman
Journal:  Cell Mol Life Sci       Date:  2011-10-04       Impact factor: 9.261

2.  Metagenomics and personalized medicine.

Authors:  Herbert W Virgin; John A Todd
Journal:  Cell       Date:  2011-09-30       Impact factor: 41.582

3.  The Intestinal Microbiota Influences Campylobacter jejuni Colonization and Extraintestinal Dissemination in Mice.

Authors:  Jason L O'Loughlin; Derrick R Samuelson; Andrea G Braundmeier-Fleming; Bryan A White; Gary J Haldorson; Jennifer B Stone; Jeremy J Lessmann; Tyson P Eucker; Michael E Konkel
Journal:  Appl Environ Microbiol       Date:  2015-05-01       Impact factor: 4.792

4.  Chronic intestinal inflammation induces stress-response genes in commensal Escherichia coli.

Authors:  Laura G Patwa; Ting-Jia Fan; Sandrine Tchaptchet; Yang Liu; Yves A Lussier; R Balfour Sartor; Jonathan J Hansen
Journal:  Gastroenterology       Date:  2011-07-02       Impact factor: 22.682

5.  Nod1 and Nod2 signaling does not alter the composition of intestinal bacterial communities at homeostasis.

Authors:  Susan J Robertson; Jun Yu Zhou; Kaoru Geddes; Stephen J Rubino; Joon Ho Cho; Stephen E Girardin; Dana J Philpott
Journal:  Gut Microbes       Date:  2013-04-02

Review 6.  Novel perspectives on therapeutic modulation of the gut microbiota.

Authors:  Justin L McCarville; Alberto Caminero; Elena F Verdu
Journal:  Therap Adv Gastroenterol       Date:  2016-04-04       Impact factor: 4.409

7.  Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.

Authors:  Sufeng Zhang; Robert Langer; Giovanni Traverso
Journal:  Nano Today       Date:  2017-10-09       Impact factor: 20.722

8.  Group Living and Male Dispersal Predict the Core Gut Microbiome in Wild Baboons.

Authors:  Laura E Grieneisen; Josh Livermore; Susan Alberts; Jenny Tung; Elizabeth A Archie
Journal:  Integr Comp Biol       Date:  2017-10-01       Impact factor: 3.326

Review 9.  The role of the commensal microbiota in adaptive and maladaptive stressor-induced immunomodulation.

Authors:  Amy R Mackos; Ross Maltz; Michael T Bailey
Journal:  Horm Behav       Date:  2016-10-17       Impact factor: 3.587

Review 10.  Immune Responses to Intestinal Microbes in Inflammatory Bowel Diseases.

Authors:  Jonathan J Hansen
Journal:  Curr Allergy Asthma Rep       Date:  2015-10       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.